Immunologic Disease clinical trials at UC Irvine

• Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

  open to eligible people ages 18 years and up

  This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.

  Irvine, California and other locations

Last updated: November 20, 2020